Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем - Журнал Системные Гипертензии Том 12, №2
Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем
Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., Шарипова Г.Х. Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем. Системные гипертензии. 2015; 12 (2): 6–7.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Carver JR, Szalda D, Ky B. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin Oncol 2013; 40: 229–38.
2. Sawaya H, Sebag I, Plana J et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596–603.
3. Bar-Joseph H, Ben-Aharon I, Tzabari M et al. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 2011; 6: e23492.
4. Chaosuwannakit N, D’Agostino R, Hamilton CA et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010; 28: 166–72.
5. Drafts BC, Twomley KM, D’Agostino R Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6: 877–85.
6. Kalabova H, Melichar B, Ungermann L et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 2011; 28: 1281–7.
7. Mizia-Stec K, Goscinska A, Mizia M et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol 2013; 71: 681–90.
8. Сardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910–6.
9. Ky B, Putt M., Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and trastuzumab. JACC 2014; 63 (8): 809–16.
10. Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002–2012 гг. Вестн. РАМН. 2013; 2: 4–11. / Chazova I.E., Oshchepkova E.V. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. RAMN. 2013; 2: 4–11. [in Russian]
11. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54 (10): 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54 (10): 4–12. [in Russian]
12. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
14. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73
15. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
16. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
17. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
18. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363–9.
19. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveil-lance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
20. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
21. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
22. Schmidt A, Gruber U, Bohmig G et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
23. Fujihara CK, Noronha IL, Malheiros Antunes GR et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283–90.
24. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams & Wilkins, 2003; p. 516–9.
25. Luft FC. Erythropoietin and arterial hypertension. Clin Nephrol 2000; 53: S61–4.
2. Sawaya H, Sebag I, Plana J et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596–603.
3. Bar-Joseph H, Ben-Aharon I, Tzabari M et al. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 2011; 6: e23492.
4. Chaosuwannakit N, D’Agostino R, Hamilton CA et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010; 28: 166–72.
5. Drafts BC, Twomley KM, D’Agostino R Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6: 877–85.
6. Kalabova H, Melichar B, Ungermann L et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 2011; 28: 1281–7.
7. Mizia-Stec K, Goscinska A, Mizia M et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol 2013; 71: 681–90.
8. Сardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910–6.
9. Ky B, Putt M., Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and trastuzumab. JACC 2014; 63 (8): 809–16.
10. Chazova I.E., Oshchepkova E.V. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. RAMN. 2013; 2: 4–11. [in Russian]
11. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54 (10): 4–12. [in Russian]
12. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
14. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73
15. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
16. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
17. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
18. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363–9.
19. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveil-lance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
20. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
21. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
22. Schmidt A, Gruber U, Bohmig G et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
23. Fujihara CK, Noronha IL, Malheiros Antunes GR et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283–90.
24. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams & Wilkins, 2003; p. 516–9.
25. Luft FC. Erythropoietin and arterial hypertension. Clin Nephrol 2000; 53: S61–4.
2. Sawaya H, Sebag I, Plana J et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596–603.
3. Bar-Joseph H, Ben-Aharon I, Tzabari M et al. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 2011; 6: e23492.
4. Chaosuwannakit N, D’Agostino R, Hamilton CA et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010; 28: 166–72.
5. Drafts BC, Twomley KM, D’Agostino R Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6: 877–85.
6. Kalabova H, Melichar B, Ungermann L et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 2011; 28: 1281–7.
7. Mizia-Stec K, Goscinska A, Mizia M et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol 2013; 71: 681–90.
8. Сardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910–6.
9. Ky B, Putt M., Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and trastuzumab. JACC 2014; 63 (8): 809–16.
10. Чазова И.Е., Ощепкова Е.В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002–2012 гг. Вестн. РАМН. 2013; 2: 4–11. / Chazova I.E., Oshchepkova E.V. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. RAMN. 2013; 2: 4–11. [in Russian]
11. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54 (10): 4–12. / Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54 (10): 4–12. [in Russian]
12. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
14. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73
15. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
16. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
17. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
18. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363–9.
19. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveil-lance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
20. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
21. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
22. Schmidt A, Gruber U, Bohmig G et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
23. Fujihara CK, Noronha IL, Malheiros Antunes GR et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283–90.
24. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams & Wilkins, 2003; p. 516–9.
25. Luft FC. Erythropoietin and arterial hypertension. Clin Nephrol 2000; 53: S61–4.
________________________________________________
2. Sawaya H, Sebag I, Plana J et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596–603.
3. Bar-Joseph H, Ben-Aharon I, Tzabari M et al. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS One 2011; 6: e23492.
4. Chaosuwannakit N, D’Agostino R, Hamilton CA et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010; 28: 166–72.
5. Drafts BC, Twomley KM, D’Agostino R Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013; 6: 877–85.
6. Kalabova H, Melichar B, Ungermann L et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 2011; 28: 1281–7.
7. Mizia-Stec K, Goscinska A, Mizia M et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodelling. Kardiol Pol 2013; 71: 681–90.
8. Сardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910–6.
9. Ky B, Putt M., Sawaya H. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and trastuzumab. JACC 2014; 63 (8): 809–16.
10. Chazova I.E., Oshchepkova E.V. Itogi realizatsii Federal'noi tselevoi programmy po profilaktike i lecheniiu arterial'noi gipertenzii v Rossii v 2002–2012 gg. Vestn. RAMN. 2013; 2: 4–11. [in Russian]
11. Chazova I.E., Zhernakova Iu.V., Oshchepkova E.V. i dr. Rasprostranennost' faktorov riska serdechno-sosudistykh zabolevanii v rossiiskoi populiatsii bol'nykh arterial'noi gipertoniei. Kardiologiia. 2014; 54 (10): 4–12. [in Russian]
12. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
13. Brookes L. National Health and Nutrition Examination Survey (NHANES) data on hypertension. In: American Society of Hypertension 18th Annual Scientific Session. 2003.
14. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011; 103: 763–73
15. Wijermans PW, Lubbert M, Verhoef G et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2-deoxycytidine (decitabine) in177 patients. Ann Hematol 2005; 84 (Suppl. 1): 9–17.
16. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7: 193–201.
17. Chu TF, Rupnick MA. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9.
18. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363–9.
19. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveil-lance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596–604.
20. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer 2011; 10: 151–6.
21. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 2011; 124: 1687–91.
22. Schmidt A, Gruber U, Bohmig G et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 2001; 16: 1034–7.
23. Fujihara CK, Noronha IL, Malheiros Antunes GR et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283–90.
24. Grossman EMF. Management of drug-induced and iatrogenic hypertension. In: Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams & Wilkins, 2003; p. 516–9.
25. Luft FC. Erythropoietin and arterial hypertension. Clin Nephrol 2000; 53: S61–4.
Авторы
И.Е.Чазова, Е.В.Ощепкова, М.Ю.Кириллова, Г.Х.Шарипова*
Институт клинической кардиологии им. А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а
*register.ihd.rus@gmail.com
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a
*register.ihd.rus@gmail.com
Институт клинической кардиологии им. А.Л.Мясникова ФГБУ Российский кардиологический научно-производственный комплекс Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15а
*register.ihd.rus@gmail.com
________________________________________________
A.L.Myasnikov Institute of Clinical Cardiology, Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a
*register.ihd.rus@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.